Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

437
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
437
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

470
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
470
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.5K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.5K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

286
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
286
Surface Membrane Barriers01:18

Surface Membrane Barriers

1.8K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.8K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

604
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
604

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mucoactive therapies and the European Respiratory Society guideline for adult bronchiectasis: what now after the CLEAR trial?

The European respiratory journal·2026
Same author

Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial.

American journal of respiratory and critical care medicine·2026
Same author

Find your career: the ERS "My Career Path" series.

Breathe (Sheffield, England)·2026
Same author

The European Respiratory Society guideline for management of adult bronchiectasis: clinical summary.

Breathe (Sheffield, England)·2026
Same author

Multidrug-resistant <i>Haemophilus influenzae</i> cluster of severe asthma from sputum bacteriome-resistome.

ERJ open research·2026
Same author

Targeting Inflammation in Bronchiectasis.

Drugs·2026

Related Experiment Video

Updated: Oct 31, 2025

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

3.6K

Mucus, Microbiomes and Pulmonary Disease.

Oliver W Meldrum1, Sanjay H Chotirmall1

  • 1Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore.

Biomedicines
|July 2, 2021
PubMed
Summary

Healthy mucus is vital for lung health, supporting a balanced microbiome. This review explores how mucin, a key mucus component, influences lung microbes and disease, offering new treatment avenues.

Keywords:
microbiomemucinmucuspulmonary disease

More Related Videos

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.3K
Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
07:38

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome

Published on: August 3, 2021

2.6K

Related Experiment Videos

Last Updated: Oct 31, 2025

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

3.6K
The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.3K
Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
07:38

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome

Published on: August 3, 2021

2.6K

Area of Science:

  • Microbiology
  • Pulmonary Physiology
  • Immunology

Background:

  • The respiratory tract hosts a diverse microbial community within the mucus layer, crucial for lung health.
  • Maintaining healthy mucus is essential for pulmonary function, immune tolerance, and a stable lung microbiome.
  • Factors like smoking, diet, and infection can disrupt lung microbial homeostasis.

Purpose of the Study:

  • To review the role of polymerizing mucin in the mucus layer of the respiratory tract.
  • To discuss how mucin influences microbial behavior and lung homeostasis.
  • To explore the connection between mucus compromise, inflammation, and microbial dysbiosis in chronic respiratory diseases.

Main Methods:

  • Literature review focusing on mucin structure-function relationships in the respiratory tract.
  • Analysis of how mucin composition and organization impact microbial communities.
  • Synthesis of current research on mucus as a biomarker and therapeutic target.

Main Results:

  • Polymerizing mucin is a key functional component of the mucus layer, with altered properties during pulmonary disease.
  • Mucin's physical and chemical characteristics directly influence microbial behavior and lung microbiome composition.
  • A compromised mucus layer is linked to increased inflammation and microbial dysbiosis.

Conclusions:

  • Mucus and its mucin components play a critical role in maintaining a healthy lung microbiome and preventing disease.
  • Mucus layer integrity and mucin function can serve as predictors of infection risk and disease severity.
  • Understanding mucin dynamics offers new therapeutic strategies, including mucolytic treatments, for chronic pulmonary conditions.